 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || AB-1015 / ArsenalBio
Enrollment closed: AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients with Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov) - Sep 20, 2024
P1, N=60, Active, not recruiting, Sponsor: Arsenal Biosciences, Inc.
Recruiting --> Active, not recruiting
- || AB-1015 / ArsenalBio
Trial primary completion date: AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients with Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov) - May 7, 2024
P1, N=60, Recruiting, Sponsor: Arsenal Biosciences, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2024 --> Dec 2024
- AB-1015 / ArsenalBio
Characterization of AB-1015 logic-gated CAR induction (ON kinetics), receptor turnover (OFF kinetics), and logic gate sensitivity to ALPG/P and MSLN (Section 40) - Mar 5, 2024 - Abstract #AACR2024AACR_7716;
P1
Finally, the in vivo specificity of AB-1015 for ALPG+/MSLN+ tumors was established using a dual flank specificity model. Together, these data support the continued development of AB-1015 in a phase I clinical trial (NCT05617755).
- AB-1015 / ArsenalBio
Development of a robust manufacturing process for AB-1015, an integrated circuit T cell (ICT) products, using targeted, CRISPR integration of transgenes by electroporation (CITE) editing (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1004;
Billions of ICT cells can be generated from a single healthy donor in a semi-closed, semi-automated fashion and these ICT cells display potent anti-tumor activity in vitro and in vivo with high specificity in preclinical studies. AB-1015 is currently in Phase 1 clinical trials.
- AB-1015 / ArsenalBio
Preclinical development of AB-1015, an integrated circuit T cell therapy containing an ALPG/MSLN logic gate and FAS/PTPN2 shRNA-miR, for the treatment of ovarian cancer (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_687;
P1
Conclusions AB-1015 is specific for ALPG/P+MSLN+, demonstrates superior potency compared with logic gated T cells alone, and is resistant to ovarian TME suppression in preclinical studies. Based on these promising preclinical data, AB-1015 is being studied in a phase I clinical trial (NCT05617755).
- AB-1015 / ArsenalBio
Preclinical Development of AB-1015, an Integrated Circuit T Cell Therapy Containing an ALPG/MSLN Logic Gate and FAS/PTPN2 shRNA-miR, for the Treatment of Ovarian Cancer (Room 502 AB) - Apr 6, 2023 - Abstract #ASGCT2023ASGCT_818;
P1
As a result, AB-1015 is capable of completely clearing these otherwise difficult-to-treat tumors in this model.In summary, AB-1015 is specific for ALPG/P+MSLN+, demonstrates superior potency, expansion, and persistence compared with logic gated T cells alone, and is resistant to ovarian TME suppression in preclinical studies. Based on these promising preclinical data, AB-1015 is being studied in a phase I clinical trial (NCT05617755) to assess the safety, pharmacokinetics, immunogenicity, and efficacy for patients with platinum-resistant ovarian cancer.
- ||| AB-1015 / ArsenalBio
Enrollment open: AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients with Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov) - Nov 22, 2022
P1, N=60, Recruiting, Sponsor: Arsenal Biosciences, Inc.
Based on these promising preclinical data, AB-1015 is being studied in a phase I clinical trial (NCT05617755) to assess the safety, pharmacokinetics, immunogenicity, and efficacy for patients with platinum-resistant ovarian cancer. Not yet recruiting --> Recruiting
- | AB-1015 / ArsenalBio
New P1 trial: AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients with Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov) - Nov 15, 2022
P1, N=60, Not yet recruiting, Sponsor: Arsenal Biosciences, LLC
- AB-1015 / ArsenalBio
CRISPR/Cas9-based integration of a large and modular cassette into a safe harbor site to improve CAR T cell therapy efficacy and safety (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_669;
Our first ICT clinical program, AB-1015, is an autologous cell product for the treatment of ovarian cancer...Conclusions CITE editing at GS94 is specific and generates highly functional ICT cells. This novel approach to engineering tumor-specific T cells enables the generation of exceptional clinical candidates that both target new cancer types and improve efficacy.